Fully automated analysis of activities catalysed by the major human liver cytochrome P450(CYP) enzymes: assessment of human CYP inhibition potential

被引:130
作者
Moody, GC
Griffin, SJ
Mather, AN
McGinnity, DF
Riley, RJ [1 ]
机构
[1] Dept Phys & Metab Sci, Loughborough LE11 5RH, Leics, England
[2] Dept Med Chem, Loughborough LE11 5RH, Leics, England
关键词
D O I
10.1080/004982599238812
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
1. Fully automated inhibition screens for the major human hepatic cytochrome P450s have been developed and validated. Probe assays were the fluorometric-based ethoxyresorufin O-deethylation for CYP1A2 and radiometric analysis of erythromycin N-demethylation for CYP3A4, dextromethorphan O-demethylation for CYP2D6, naproxen O-demethylation for CYP2C9 and diazepam N-demethylation for CYP2C19. For the radiometric assays > 99.7% of C-14-labelled substrate was routinely extracted from incubations by solid-phase extraction. 2. Furafylline, sulphaphenazole, omeprazole, quinidine and ketoconazole were identified as specific markers for the respective CYP1A2 (IC50 = 6 mu M), CYP2C9 (0.7 mu M), CYP2C19 (6 mu M), CYP2D6 (0.02 mu M) and CYP3A4 (0.2 mu M) inhibition screens. 3. For the radiometric methods, a two-point IC50 estimate was validated by correlating the IC50 obtained with a full (seven-point) assay (r(2) = 0.98, P < 0.001). The two-point IC50 estimate is useful for initial screening, while the full IC50 method provides more definitive quantitation, where required. 4. IC50 determined for a series of test compounds in human liver microsomes and cytochrome P450 cDNA-expressed enzymes were similar (r(2) = 0.89, P < 0.001). In particular, the CYP1A2, CYP2D6 and CYP3A4 screens demonstrated the flexibility to accept either enzyme source. As a result of incomplete substrate selectivity, expressed enzymes were utilized for analysis of CYP2C9 and CYP2C19 inhibition. Good agreement was demonstrated between IC50 determined in these assays to ICS, published by other laboratories using a wide range of analytical techniques, which provided confidence in the universality of these inhibition screens. 5. These automated screens for initial assessment of P450 inhibition potential allow rapid determination of IC50. The radiometric assays are flexible, sensitive, robust and free from analytical interference, and they should permit the identification and eradication of inhibitory structural motifs within a series of potential drug candidates.
引用
收藏
页码:53 / 75
页数:23
相关论文
共 81 条
[1]   CISAPRIDE AND TORSADES-DE-POINTES [J].
AHMAD, SR ;
WOLFE, SM .
LANCET, 1995, 345 (8948) :508-508
[2]   DIAZEPAM METABOLISM BY HUMAN LIVER-MICROSOMES IS MEDIATED BY BOTH S-MEPHENYTOIN HYDROXYLASE AND CYP3A ISOFORMS [J].
ANDERSSON, T ;
MINERS, JO ;
VERONESE, ME ;
BIRKETT, DJ .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1994, 38 (02) :131-137
[3]   IDENTIFICATION OF HUMAN LIVER CYTOCHROME-P450 ISOFORMS MEDIATING OMEPRAZOLE METABOLISM [J].
ANDERSSON, T ;
MINERS, JO ;
VERONESE, ME ;
TASSANEEYAKUL, W ;
TASSANEEYAKUL, W ;
MEYER, UA ;
BIRKETT, DJ .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1993, 36 (06) :521-530
[4]   ESTRADIOL METABOLISM BY COMPLEMENTARY DEOXYRIBONUCLEIC ACID-EXPRESSED HUMAN CYTOCHROME-P450S [J].
AOYAMA, T ;
KORZEKWA, K ;
NAGATA, K ;
GILLETTE, J ;
GELBOIN, HV ;
GONZALEZ, FJ .
ENDOCRINOLOGY, 1990, 126 (06) :3101-3106
[5]  
Ayrton J, 1998, RAPID COMMUN MASS SP, V12, P217, DOI 10.1002/(SICI)1097-0231(19980314)12:5<217::AID-RCM146>3.0.CO
[6]  
2-I
[7]   INVITRO INHIBITION STUDIES OF TOLBUTAMIDE HYDROXYLASE-ACTIVITY OF HUMAN-LIVER MICROSOMES BY AZOLES, SULFONAMIDES AND QUINOLINES [J].
BACK, DJ ;
TJIA, JF ;
KARBWANG, J ;
COLBERT, J .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1988, 26 (01) :23-29
[8]   KETOCONAZOLE AND SULFAPHENAZOLE AS THE RESPECTIVE SELECTIVE INHIBITORS OF P4503A AND 2C9 [J].
BALDWIN, SJ ;
BLOOMER, JC ;
SMITH, GJ ;
AYRTON, AD ;
CLARKE, SE ;
CHENERY, RJ .
XENOBIOTICA, 1995, 25 (03) :261-270
[9]   Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions [J].
Bertz, RJ ;
Granneman, GR .
CLINICAL PHARMACOKINETICS, 1997, 32 (03) :210-258
[10]   THE ROLE OF CYTOCHROME-P4502D6 IN THE METABOLISM OF PAROXETINE BY HUMAN LIVER-MICROSOMES [J].
BLOOMER, JC ;
WOODS, FR ;
HADDOCK, RE ;
LENNARD, MS ;
TUCKER, GT .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1992, 33 (05) :521-523